As we reached the end of June last week, we review moves from smid-cap biopharma companies during the month of June. See Table 1 for monthly moves and moves YTD for companies and categories on BPIQ.com compared to XBI. To subscribe to BPIQ companies Learn more here.
Table 1. BPIQ company monthly moves and YTD moves
Category | June Moves | YTD Move |
|---|---|---|
All BPIQ Companies | +2.97% | -43.39% |
CAR-T Companies | +3.99% | -52.32% |
Gene Editing Companies | +12.18% | -45.20% |
XBI | +7.98% | -27.66% |
See the biggest moves from last month below:
Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!
*We never send you spam - unsubscribe anytime
Highlights for the week
Biggest positive move
#EPZM +250% Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology.
Biggest negative move
#PRAX -70.48% Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder
Additional weekly big moves
#EVFM +213.9% Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi®
#DAWN +187.8% Day One Announces Pricing of Upsized Public Offering of Common Stock
#CLVS +157.1% Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status
#RAIN +139.7%
#WVE +132.14% Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering
#ALT +131.23% Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022
#MREO +119.61% Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan
#BMEA +118.21% Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes
#TPTX +112.75% Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies
#CALA -40.15% Calithera Biosciences Announces 1-for-20 Reverse stock split
#HUMA -40.88% Humacyte Presents New Immunogenicity Data on Human Acellular Vessels™ (HAVs™)
#NMTR -42.22% 9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome.
#IMUX -44.03% Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update
#RLYB -44.49%
#TALS -47.62% Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update
#LBPS -48.76%
#ENOB -63.31%
#ATHA -66.41% Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
#AGLE -67.72% Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency
#ADXN -69.50% Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate
Highlights for this week
To see this week's Big Movers HERE, subscribe. Learn more here.
$HZNP KRYSTEXXA PDUFA
See our new July PDUFA list
See our Big Movers post to learn about upcoming Movers throughout July and PDUFAs, after subscribing. Learn more here.
Comments